Drug General Information (ID: DDIHF4LC6T)
Drug Name			Rubella virus vaccine		Drug Info		Ocrelizumab		Drug Info
Drug Type		Vaccine				Monoclonal antibody
Therapeutic Class		Vaccine				Antineoplastics

Mechanism of Rubella virus vaccine-Ocrelizumab Interaction (Severity Level: Major)
Antagonize the effect of vaccine/toxoid Click to Show/Hide Mechanism Graph
Drug Name		Rubella virus vaccine				Ocrelizumab
Mechanism		Vaccine or toxoid				Immunosuppressive effects
Key Mechanism Factor 1
		Factor Name		Vaccine/toxoid
		Factor Description		The beneficial effects of the vaccine/toxinoid may be reduced, leading to a diminished or suboptimal immune response.
Mechanism Description		Antagonize the effect of Rubella virus vaccine when combined with Ocrelizumab

Recommended Action
Management		Live virus or bacterial vaccines should not be administered to patients during therapy or after discontinuing ocrelizumab therapy until recovery from B-cell repletion occurs. Immunization status should be assessed prior to initiating ocrelizumab and recommended immunization with live or attenuated live vaccines should be completed at least 4 weeks prior to ocrelizumab initiation (some authorities have recommended at least 6 weeks). For infants of mothers exposed to ocrelizumab during pregnancy, live or live-attenuated vaccines should be delayed until B-cell levels have recovered therefore, measuring CD19 positive B-cell levels prior to vaccination in these infants is recommended.

References
1	CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
2	Cerner Multum, Inc. "Australian Product Information.".
3	Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. "Harrison's Principles of Internal Medicine. 14th ed." New York, NY: McGraw-Hill Health Professionals Division (1998).